;PMID: 9578594
;source_file_970.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..44] = [t:0..44]
;1)sentence:[e:50..143] = [t:50..143]
;2)section:[e:147..167] = [t:147..167]
;3)section:[e:171..259] = [t:171..259]
;4)sentence:[e:263..419] = [t:263..419]
;5)sentence:[e:421..574] = [t:421..574]
;6)sentence:[e:576..694] = [t:576..694]
;7)sentence:[e:695..855] = [t:695..855]
;8)sentence:[e:856..1046] = [t:856..1046]
;9)sentence:[e:1047..1215] = [t:1047..1215]
;10)sentence:[e:1216..1458] = [t:1216..1458]
;11)sentence:[e:1459..1574] = [t:1459..1574]
;12)sentence:[e:1575..1757] = [t:1575..1757]
;13)section:[e:1758..1788] = [t:1758..1788]
;14)section:[e:1792..1836] = [t:1792..1836]

;section 0 Span:0..44
;Arch Biochem Biophys. 1998 May 1;353(1):1-9.
(SEC
  (FRAG (NNP:[0..4] Arch) (NNP:[5..12] Biochem) (DT:[13..20] Biophys)
        (JJ:[20..21] .) (CD:[22..26] 1998) (NNP:[27..30] May)
        (CD:[31..37] 1;353-LRB-) (CD:[37..38] 1) (-RRB-:[38..39] -RRB-)
        (CD:[39..41] :1) (HYPH:[41..42] -) (CD:[42..44] 9.)))

;sentence 1 Span:50..143
;Posttranslational elevation of cytochrome P450 3A levels and activity by 
;dimethyl sulfoxide.
;[81..99]:cyp450:"cytochrome P450 3A"
;[124..142]:substance:"dimethyl sulfoxide"
(SENT
  (NP-HLN
    (NP (JJ:[50..67] Posttranslational) (NN:[68..77] elevation))
    (PP (IN:[78..80] of)
      (NP
        (NP
          (NML-1 (NN:[81..91] cytochrome) (NN:[92..96] P450) (NN:[97..99] 3A))
          (NNS:[100..106] levels))
        (CC:[107..110] and)
        (NP
          (NML-1 (-NONE-:[110..110] *P*))
          (NN:[111..119] activity))))
    (PP (IN:[120..122] by)
      (NP (JJ:[124..132] dimethyl) (NN:[133..142] sulfoxide)))
    (.:[142..143] .)))

;section 2 Span:147..167
;Zangar RC, Novak RF.
(SEC
  (FRAG (NNP:[147..153] Zangar) (NNP:[154..156] RC) (,:[156..157] ,)
        (NNP:[158..163] Novak) (NNP:[164..167] RF.)))

;section 3 Span:171..259
;Institute of Chemical Toxicology, Wayne State University, Detroit, Michigan 
;48201, USA.
(SEC
  (FRAG (NNP:[171..180] Institute) (IN:[181..183] of) (NNP:[184..192] Chemical)
        (NNP:[193..203] Toxicology) (,:[203..204] ,) (NNP:[205..210] Wayne)
        (NNP:[211..216] State) (NNP:[217..227] University) (IN:[227..228] ,)
        (NNP:[229..236] Detroit) (,:[236..237] ,) (NNP:[238..246] Michigan)
        (VBZ:[248..253] 48201) (NNP:[253..254] ,) (NNP:[255..258] USA)
        (.:[258..259] .)))

;sentence 4 Span:263..419
;The molecular mechanisms by which dimethyl sulfoxide (DMSO) enhances CYP3A 
;protein in phenobarbital-treated primary cultured rat hepatocytes were
;examined.
;[297..315]:substance:"dimethyl sulfoxide"
;[317..321]:substance:"DMSO"
;[332..346]:cyp450:"CYP3A  protein"
;[350..363]:substance:"phenobarbital"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[263..266] The) (JJ:[267..276] molecular)
          (NNS:[277..287] mechanisms))
      (SBAR
        (WHPP-1 (IN:[288..290] by)
          (WHNP (WDT:[291..296] which)))
        (S
          (NP-SBJ
            (NP (JJ:[297..305] dimethyl) (NN:[306..315] sulfoxide))
            (NP (-LRB-:[316..317] -LRB-) (NN:[317..321] DMSO)
                (-RRB-:[321..322] -RRB-)))
          (VP (VBZ:[323..331] enhances)
            (NP (NN:[332..337] CYP3A) (NN:[339..346] protein))
            (PP-LOC (IN:[347..349] in)
              (NP
                (ADJP (NN:[350..363] phenobarbital) (HYPH:[363..364] -)
                      (VBN:[364..371] treated))
                (JJ:[372..379] primary) (VBN:[380..388] cultured)
                 (NN:[389..392] rat) (NNS:[393..404] hepatocytes)))
            (PP-MNR-1 (-NONE-:[404..404] *T*))))))
    (VP (VBD:[405..409] were)
      (VP (VBN:[410..418] examined)
        (NP-2 (-NONE-:[418..418] *))))
    (.:[418..419] .)))

;sentence 5 Span:421..574
;DMSO treatment rapidly increased CYP3A protein levels in the absence of an 
;increase in CYP3A mRNA levels or an increase in CYP2B protein or mRNA
;levels.
;[421..425]:substance:"DMSO"
;[454..467]:cyp450:"CYP3A protein"
;[509..519]:substance:"CYP3A mRNA"
;[545..558]:cyp450:"CYP2B protein"
;[562..566]:substance:"mRNA"
(SENT
  (S
    (NP-SBJ (NN:[421..425] DMSO) (NN:[426..435] treatment))
    (ADVP (RB:[436..443] rapidly))
    (VP (VBD:[444..453] increased)
      (NP
         (NN:[454..459] CYP3A) (NN:[460..467] protein)
        (NNS:[468..474] levels))
      (PP (IN:[475..477] in)
        (NP
          (NP (DT:[478..481] the) (NN:[482..489] absence))
          (PP (IN:[490..492] of)
            (NP
              (NP
                (NP (DT:[493..495] an) (NN:[497..505] increase))
                (PP (IN:[506..508] in)
                  (NP
                     (NN:[509..514] CYP3A) (NN:[515..519] mRNA)
                    (NNS:[520..526] levels))))
              (CC:[527..529] or)
              (NP
                (NP (DT:[530..532] an) (NN:[533..541] increase))
                (PP (IN:[542..544] in)
                  (NP
                    (NP
                      (NML-1 (NN:[545..550] CYP2B))
                      (NN:[551..558] protein))
                    (CC:[559..561] or)
                    (NP
                      (NML-1 (-NONE-:[561..561] *P*))
                      (NN:[562..566] mRNA) (NNS:[567..573] levels))))))))))
    (.:[573..574] .)))

;sentence 6 Span:576..694
;CYP3A levels were increased approximately 3.7- and 9-fold following 0.1% DMSO
; treatment for 6 and 48 h, respectively.
;[576..581]:cyp450:"CYP3A"
;[604..622]...[629..633]:quantitative-value:"approximately 3.7-"..."fold"
;[604..617]...[627..633]:quantitative-value:"approximately"..."9-fold"
;[644..648]:quantitative-value:"0.1%"
;[649..653]:substance:"DMSO"
;[669..670]:quantitative-value:"6"
;[675..677]:quantitative-value:"48"
;[678..679]:quantitative-units:"h"
(SENT
  (S
    (NP-SBJ-4 (NN:[576..581] CYP3A) (NNS:[582..588] levels))
    (VP (VBD:[589..593] were)
      (VP (VBN:[594..603] increased)
        (NP-4 (-NONE-:[603..603] *))
        (ADVP-EXT
          (ADVP
            (QP
              (ADVP-3 (RB:[604..617] approximately))
              (CD:[618..621] 3.7) (HYPH:[621..622] -)
              (ADVP-2 (-NONE-:[622..622] *P*))))
          (CC:[623..626] and)
          (ADVP
            (QP
              (ADVP-3 (-NONE-:[626..626] *P*))
              (CD:[627..628] 9) (HYPH:[628..629] -)
              (ADVP-2 (RB:[629..633] fold)))))
        (PP (VBG:[634..643] following)
          (NP
            (NP
              (NML (CD:[644..647] 0.1) (NN:[647..648] %))
              (NN:[649..653] DMSO) (NN:[655..664] treatment))
            (PP-TMP (IN:[665..668] for)
              (NP
                (NP (CD:[669..670] 6)
                  (NML-1 (-NONE-:[670..670] *P*)))
                (CC:[671..674] and)
                (NP (CD:[675..677] 48)
                  (NML-1 (NN:[678..679] h)))))
            (,:[679..680] ,)
            (ADVP (RB:[681..693] respectively))))))
    (.:[693..694] .)))

;sentence 7 Span:695..855
;Analyses of the polysomal distribution  of CYP3A mRNA suggested that DMSO
;treatment did not significantly alter the  translational efficiency of the
;CYP3A mRNA.
;[738..748]:substance:"CYP3A mRNA"
;[764..768]:substance:"DMSO"
;[844..854]:substance:"CYP3A mRNA"
(SENT
  (S
    (NP-SBJ
      (NP (NNS:[695..703] Analyses))
      (PP (IN:[704..706] of)
        (NP
          (NP (DT:[707..710] the) (JJ:[711..720] polysomal)
              (NN:[721..733] distribution))
          (PP (IN:[735..737] of)
            (NP (NN:[738..743] CYP3A) (NN:[744..748] mRNA))))))
    (VP (VBD:[749..758] suggested)
      (SBAR (IN:[759..763] that)
        (S
          (NP-SBJ (NN:[764..768] DMSO) (NN:[769..778] treatment))
          (VP (VBD:[779..782] did) (RB:[783..786] not)
            (ADVP (RB:[787..800] significantly))
            (VP (VB:[801..806] alter)
              (NP
                (NP (DT:[807..810] the) (JJ:[812..825] translational)
                    (NN:[826..836] efficiency))
                (PP (IN:[837..839] of)
                  (NP (DT:[840..843] the)
                     (NN:[844..849] CYP3A) (NN:[850..854] mRNA)))))))))
    (.:[854..855] .)))

;sentence 8 Span:856..1046
;Comparative analyses of  immunodetectable protein levels following treatment
;with cycloheximide showed  that DMSO clearly decreased the rate of CYP3A
;protein turnover but not that of  CYP2B.
;[898..905]:substance:"protein"
;[938..951]:substance:"cycloheximide"
;[965..969]:substance:"DMSO"
;[1000..1013]:cyp450:"CYP3A protein"
;[1040..1045]:cyp450:"CYP2B"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[856..867] Comparative) (NNS:[868..876] analyses))
      (PP (IN:[877..879] of)
        (NP (JJ:[881..897] immunodetectable) (NN:[898..905] protein)
            (NNS:[906..912] levels)))
      (PP (VBG:[913..922] following)
        (NP
          (NP (NN:[923..932] treatment))
          (PP (IN:[933..937] with)
            (NP (NN:[938..951] cycloheximide))))))
    (VP (VBD:[952..958] showed)
      (SBAR (IN:[960..964] that)
        (S
          (NP-SBJ (NN:[965..969] DMSO))
          (ADVP (RB:[970..977] clearly))
          (VP
            (VP (VBD:[978..987] decreased)
              (NP
                (NP (DT:[988..991] the) (NN:[992..996] rate))
                (PP=1 (IN:[997..999] of)
                  (NP
                     (NN:[1000..1005] CYP3A) (NN:[1006..1013] protein)
                    (NN:[1014..1022] turnover)))))
            (CC:[1023..1026] but)
            (VP (RB:[1027..1030] not)
              (NP
                (NP (DT:[1031..1035] that))
                (PP=1 (IN:[1036..1038] of)
                  (NP (NN:[1040..1045] CYP2B)))))))))
    (.:[1045..1046] .)))

;sentence 9 Span:1047..1215
;Examination of testosterone metabolism in hepatocyte cultures revealed  that
;DMSO pretreatment increased CYP3A-catalyzed 2 beta- and 6 beta-testosterone 
;hydroxylation.
;[1062..1074]:substance:"testosterone"
;[1124..1128]:substance:"DMSO"
;[1152..1157]:cyp450:"CYP3A"
;[1187..1199]:substance:"testosterone"
(SENT
  (S
    (NP-SBJ
      (NP (NN:[1047..1058] Examination))
      (PP (IN:[1059..1061] of)
        (NP
          (NP (NN:[1062..1074] testosterone) (NN:[1075..1085] metabolism))
          (PP-LOC (IN:[1086..1088] in)
            (NP (NN:[1089..1099] hepatocyte) (NNS:[1100..1108] cultures))))))
    (VP (VBD:[1109..1117] revealed)
      (SBAR (IN:[1119..1123] that)
        (S
          (NP-SBJ (NN:[1124..1128] DMSO) (NN:[1129..1141] pretreatment))
          (VP (VBD:[1142..1151] increased)
            (NP
              (NP
                (ADJP-1 (NN:[1152..1157] CYP3A) (HYPH:[1157..1158] -)
                        (VBN:[1158..1167] catalyzed))
                (NML (CD:[1168..1169] 2) (SYM:[1170..1174] beta)
                     (HYPH:[1174..1175] -)
                  (NML-2 (-NONE-:[1175..1175] *P*)))
                (NML-3 (-NONE-:[1175..1175] *P*)))
              (CC:[1176..1179] and)
              (NP
                (ADJP-1 (-NONE-:[1179..1179] *P*))
                (NML (CD:[1180..1181] 6) (SYM:[1182..1186] beta)
                     (HYPH:[1186..1187] -)
                  (NML-2 (NN:[1187..1199] testosterone)))
                (NML-3 (NN:[1201..1214] hydroxylation))))))))
    (.:[1214..1215] .)))

;sentence 10 Span:1216..1458
;When DMSO was in the culture medium, no inhibitory affect on  CYP3A-catalyzed
;testosterone metabolism was observed, although a slight (15-21%)  inhibitory
;effect was noted for CYP2B-catalyzed 16 alpha- and 16  beta-testosterone
;hydroxylation.
;[1221..1225]:substance:"DMSO"
;[1245..1251]:substance:"medium"
;[1278..1283]:cyp450:"CYP3A"
;[1294..1306]:substance:"testosterone"
;[1351..1357]:quantitative-value:"15-21%"
;[1392..1397]:cyp450:"CYP2B"
;[1431..1443]:substance:"testosterone"
(SENT
  (S
    (SBAR-ADV
      (WHADVP-6 (WRB:[1216..1220] When))
      (S
        (NP-SBJ (NN:[1221..1225] DMSO))
        (VP (VBD:[1226..1229] was)
          (PP-LOC-PRD (IN:[1230..1232] in)
            (NP (DT:[1233..1236] the) (NN:[1237..1244] culture)
                (NN:[1245..1251] medium)))
          (ADVP-TMP-6 (-NONE-:[1251..1251] *T*)))))
    (,:[1251..1252] ,)
    (NP-SBJ-5
      (NP (DT:[1253..1255] no) (JJ:[1256..1266] inhibitory)
          (NN:[1267..1273] affect))
      (PP (IN:[1274..1276] on)
        (NP
          (ADJP (NN:[1278..1283] CYP3A) (HYPH:[1283..1284] -)
                (VBN:[1284..1293] catalyzed))
          (NN:[1294..1306] testosterone) (NN:[1307..1317] metabolism))))
    (VP (VBD:[1318..1321] was)
      (VP (VBN:[1322..1330] observed)
        (NP-5 (-NONE-:[1330..1330] *))
        (,:[1330..1331] ,)
        (SBAR-ADV (IN:[1332..1340] although)
          (S
            (NP-SBJ-4 (DT:[1341..1342] a) (JJ:[1343..1349] slight)
              (PRN (-LRB-:[1350..1351] -LRB-)
                (NP
                  (QP (CD:[1351..1353] 15) (HYPH:[1353..1354] -)
                      (CD:[1354..1356] 21))
                  (NN:[1356..1357] %))
                (-RRB-:[1357..1358] -RRB-))
              (JJ:[1360..1370] inhibitory) (NN:[1371..1377] effect))
            (VP (VBD:[1378..1381] was)
              (VP (VBN:[1382..1387] noted)
                (NP-4 (-NONE-:[1387..1387] *))
                (PP (IN:[1388..1391] for)
                  (NP
                    (NP
                      (ADJP-1 (NN:[1392..1397] CYP2B) (HYPH:[1397..1398] -)
                              (VBN:[1398..1407] catalyzed))
                      (NML (CD:[1408..1410] 16) (SYM:[1411..1416] alpha)
                           (HYPH:[1416..1417] -)
                        (NML-2 (-NONE-:[1417..1417] *P*)))
                      (NML-3 (-NONE-:[1417..1417] *P*)))
                    (CC:[1418..1421] and)
                    (NP
                      (ADJP-1 (-NONE-:[1421..1421] *P*))
                      (NML (CD:[1422..1424] 16) (SYM:[1426..1430] beta)
                           (HYPH:[1430..1431] -)
                        (NML-2 (NN:[1431..1443] testosterone)))
                      (NML-3 (NN:[1444..1457] hydroxylation)))))))))))
    (.:[1457..1458] .)))

;sentence 11 Span:1459..1574
;These data provide evidence that DMSO increased  CYP3A protein levels as a
;result of decreased protein degradation.
;[1492..1496]:substance:"DMSO"
;[1508..1521]:cyp450:"CYP3A protein"
;[1554..1561]:substance:"protein"
(SENT
  (S
    (NP-SBJ (DT:[1459..1464] These) (NNS:[1465..1469] data))
    (VP (VBP:[1470..1477] provide)
      (NP (NN:[1478..1486] evidence)
        (SBAR (IN:[1487..1491] that)
          (S
            (NP-SBJ (NN:[1492..1496] DMSO))
            (VP (VBD:[1497..1506] increased)
              (NP
                 (NN:[1508..1513] CYP3A) (NN:[1514..1521] protein)
                (NNS:[1522..1528] levels))
              (PP (IN:[1529..1531] as)
                (NP
                  (NP (DT:[1532..1533] a) (NN:[1534..1540] result))
                  (PP (IN:[1541..1543] of)
                    (NP (VBN:[1544..1553] decreased) (NN:[1554..1561] protein)
                        (NN:[1562..1573] degradation))))))))))
    (.:[1573..1574] .)))

;sentence 12 Span:1575..1757
;DMSO  increased both immunodetectable CYP3A protein levels and catalytic
;activity, in  contrast to compounds that have been reported to stabilize
;CYP3A protein and  inhibit activity.
;[1575..1579]:substance:"DMSO"
;[1613..1626]:cyp450:"CYP3A protein"
;[1674..1683]:substance:"compounds"
;[1721..1734]:cyp450:"CYP3A protein"
(SENT
  (S
    (NP-SBJ (NN:[1575..1579] DMSO))
    (VP (VBD:[1581..1590] increased)
      (NP (CC:[1591..1595] both)
        (NP (JJ:[1596..1612] immunodetectable)
           (NN:[1613..1618] CYP3A) (NN:[1619..1626] protein)
          (NNS:[1627..1633] levels))
        (CC:[1634..1637] and)
        (NP (JJ:[1638..1647] catalytic) (NN:[1648..1656] activity)))
      (,:[1656..1657] ,)
      (PP (IN:[1658..1660] in)
        (NP
          (NP (NN:[1662..1670] contrast))
          (PP (TO:[1671..1673] to)
            (NP
              (NP (NNS:[1674..1683] compounds))
              (SBAR
                (WHNP-1 (WDT:[1684..1688] that))
                (S
                  (NP-SBJ-1 (-NONE-:[1688..1688] *T*))
                  (VP (VBP:[1689..1693] have)
                    (VP (VBN:[1694..1698] been)
                      (VP (VBN:[1699..1707] reported)
                        (S
                          (NP-SBJ-1 (-NONE-:[1707..1707] *))
                          (VP (TO:[1708..1710] to)
                            (VP
                              (VP (VB:[1711..1720] stabilize)
                                (NP (NN:[1721..1726] CYP3A)
                                    (NN:[1727..1734] protein)))
                              (CC:[1735..1738] and)
                              (VP (VB:[1740..1747] inhibit)
                                (NP (NN:[1748..1756] activity))))))))))))))))
    (.:[1756..1757] .)))

;section 13 Span:1758..1788
;Copyright 1998 Academic Press.
(SEC
  (FRAG (NN:[1758..1767] Copyright) (CD:[1768..1772] 1998)
        (NNP:[1773..1781] Academic) (NNP:[1782..1787] Press) (.:[1787..1788] .)))

;section 14 Span:1792..1836
;PMID: 9578594 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1792..1796] PMID) (::[1796..1797] :) (CD:[1798..1805] 9578594)
        (IN:[1806..1807] -LSB-) (NNP:[1807..1813] PubMed) (HYPH:[1814..1815] -)
        (JJ:[1816..1823] indexed) (IN:[1824..1827] for)
        (NNP:[1828..1836] MEDLINE-RSB-)))
